PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
CCENT/2009/20 - BIOVAIL/TBZ
Acquiring
Biovail
Description
a member company of the Biovail Group; its economic activity involves the formulation, clinical trials, registration, production and marketing of pharmaceutical products.
Acquired
TBZ
Description
tetrabenazine: a drug used for the treatment of hyperkinetic movement disorders, which are associated with the central nervous system, including chorea, related to Huntington´s disease, tardive diskinesia and other diskinesias. In Portugal, this drug is marketed under the trade name of Nitoman and is distributed by UCB Pharma (Produtos Farmacêuticos) Lda.
Sector
  • Extractive and manufacturing Industries
Activity (NACE)
  • C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Applicable legislation
Art. 9(1)(a) (Law 18)
Notification thresholds
Market share
Type of merger
Conglomerate
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Case description
Notified on 26 May 2009, this merger operation consists of the acquisition, by Biovail Laboratories International (Barbados) SRL (henceforth "Biovail"), of exclusive control of the business associated with the drug TBZ (henceforth "TBZ") in Portugal, as a result of the acquisition of that business from Cambridge Laboratories Ireland Limited.
Timeline
2009-07-03
COMPETITION AUTHORITY authorizes Merger Operation No. 20/2009 - BIOVAIL/TBZ
2009-06-03
Publication of the announcement
Click here to see your activities